Replies to post #155180 on Biotech Values

[mcbio]

A nice presentation. Actually found out a couple things that didn't know about FSGS. Didn't recall Encysive ran a Phase 2 study in that indication. Said it reduced Proteinuria I believe 40%. (It should be noted Encysive's drug was pulled by Pfizer for safety)

Still think its a risky company and the lead indication has too many risks for me (safety, why Gilead/GSK don't try, etc.). Overall though a very nice presentation and I wish them luck (I still have a little Ligand and hope to reacquire more after people realize Promacta is a nice drug but not a 1B+ drug)

Disclosed around 14 minute mark that RTRX received a letter from Dr. Norm Stockbridge, head of FDA's cardio renal division, that proteinuria reduction could serve as the basis for accelerated approval for RE-021. Presumably an important comment. Also said RE-021 about 9 nM selective for ET-A and doesn't bind to ET-B. Presumably may speak to some degree to your safety concern.